## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.5% below STRENGTH zone (4.0-10.0%); PEG 6.41 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($365.34)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Waters (WAT) Sees Price Target Raised by Wells Fargo | WAT Stock News**
- Source: GuruFocus | 20251215T192822 | Somewhat-Bullish | Relevance: 100%
- Wells Fargo has maintained its "Equal-Weight" rating on Waters Corporation (WAT) but raised its price target for the company from $385 to $415. This adjustment reflects a 7.79% increase based on analyst Brandon Couillard's review. The article also provides historical analyst ratings and a company overview, including its revenue breakdown and future plans for a merger with BD's life science and diagnostics business in early 2026.

**2. Waters Corporation $WAT Holdings Cut by London Co. of Virginia**
- Source: MarketBeat | 20251214T132331 | Neutral | Relevance: 100%
- London Co. of Virginia reduced its stake in Waters Corporation (NYSE:WAT) by 2.8% in Q2, now holding 580,436 shares valued at approximately $202.6 million. Institutional investors currently own about 94.01% of the medical instruments supplier, which has a "Moderate Buy" consensus rating and a target price of $390.31. Waters reported quarterly EPS of $2.29 on revenues of $608.55 million and has a market capitalization of $22.94 billion.

**3. Thrivent Financial for Lutherans Sells 75,008 Shares of Waters Corporation $WAT**
- Source: MarketBeat | 20251214T132331 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans has reduced its stake in Waters Corporation (NYSE:WAT) by selling 75,008 shares, decreasing its position by 21.3% to 277,051 shares. This move values their remaining holding at approximately $96.7 million. Waters Corporation, a medical instruments supplier, saw several other institutional investors also adjust their holdings, while Wall Street analysts have provided mixed ratings with a consensus target price of $390.31.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $415 | $385 | +8% |
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.41 signals overvaluation risk, limited margin of safety. Forward P/E 27.0x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (1 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.9B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.41 |
| Forward P/E | 27.0 |
| Current P/E | 29.4 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.4% to -1.5% (+1.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-3.38), momentum weakening. RSI neutral at 51. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.54% (CS: 24) | Neutral |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | -3.38 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 1.136x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $385.42
- **Stop Loss:** $365.34 (5.2% risk)
- **Target:** $405.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 59
- **Position Value:** $22,739.78
- **Portfolio %:** 22.74%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*